索利那新与托特罗定疗效和不良反应的相关文献汇总分析

Literature review onefficacy and safety of solifenacin and tolterodine

目的:探索索利那新和托特罗定对于膀胱过度活动症(OAB)患者排尿次数、尿急次数、尿失禁次数、夜尿及排尿量等主要疗效指标的改善程度差异,以及两药导致口干、便秘、视觉模糊等常见不良反应的发生率差异。方法:Pub Med和万方数据库上检索比较索利那新和托特罗定单药治疗OAB的临床研究、pooled分析和meta分析,将结果进行汇总分析。结果与结论:多项试验结果中索利那新的各疗效指标数值略优于托特罗定,特别是尿急次数的减少和排尿量的增加,但差异无统计学意义。因不良反应而停药的总体发生率,托特罗定略低于索利那新;便秘的发生率托特罗定低于索利那新;而口干和视觉模糊的发生率托特罗定和索利那新5 mg基本相当。

Objective： To compare the efficacy of solifenacin succinate（SOL） and tolterodine L-tartrate（TOL）for the treatment of overactive bladder （OAB）using literature review, i.e. frequency, urgency, incontinence, nocturia, and volume voided, and safety of solifenacin and tolterodine, i.e. dry mouth, constipation, and blurred vision. Methods： Analysis was upon a review of 7 clinical studies, pooled analysis and meta-analysis on the Pubmed and Wandfang database. Results and Conclusion： Clinical trials showed Solifenacin is superior to Tolterodine on the effect indexes, most of which showed no statistical significance. The review shows that the superiority becomes obvious when the sample capacity increases.